Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study

British Journal of Haematology
Jifang ZhouGregory S Calip

Abstract

Sickle cell disease (SCD) is a congenital haemoglobinopathy that causes frequent acute care/emergency room visits and hospital admissions for affected individuals. Evidence from population-based studies demonstrating the role of hydroxycarbamide (HC, also termed hydroxyurea) in reducing hospital readmission rates is limited. Our objective was to describe the use of HC and its association with acute care utilization and readmission rates using a large, nationally-representative US health insurance claims database over a 6-year period between 2009 and 2014. We identified 20 721 SCD-related inpatient and acute care encounters. Patients had been exposed to HC within 6 months prior to admission in 4263 (21%) of SCD-related admission events. HC use was more common among children aged 10-17 years and young adults aged 18-29 years. HC was associated with lower 30-day all-cause readmission rates in adults treated with average daily doses ≥1 g (odds ratio [OR], 0·72, 95% confidence interval [CI] 0·52-0·99) and doses of 0·5-1 g (OR, 0·73, 95% CI 0·57-0·93), compared to HC treatment with average daily doses of <0·5 g; adherence to HC with proportion of days covered of ≥0·80 was also associated with significantly lower 30-day all-cause read...Continue Reading

References

Jun 1, 1996·The Journal of Pediatrics·J P ScottR J Labotka
Oct 1, 1996·The Journal of Pediatrics·S JayaboseP Visintainer
Jun 12, 1999·Journal of the American Geriatrics Society·B M PsatyC D Furberg
May 20, 2004·The Annals of Pharmacotherapy·Denise M BoudreauBarry G Saver
Apr 26, 2005·American Journal of Hematology·Samir K Ballas, Margaret Lusardi
Mar 4, 2006·Pharmacoepidemiology and Drug Safety·Susan E AndradeK Arnold Chan
Apr 10, 2009·American Journal of Hematology·Teresa L KaufAbraham G Hartzema
Nov 3, 2009·The Journal of Pediatrics·Courtney D ThornburgAlex R Kemper
Apr 8, 2010·JAMA : the Journal of the American Medical Association·David C BrousseauClaudia A Steiner
Feb 18, 2011·American Journal of Hematology·Sean D CandrilliRajesh Balkrishnan
Mar 5, 2011·Current Opinion in Hematology·Patrick T McGann, Russell E Ware
Sep 3, 2013·Archives of Disease in Childhood·Mercy MulakuMike English
Sep 15, 2015·Expert Opinion on Drug Safety·Patrick T McGann, Russell E Ware
Oct 21, 2016·American Journal of Hematology·Jin HanVictor R Gordeuk
Jan 10, 2017·The American Journal of Medicine·Max A BrodskyAdetola A Kassim
Apr 20, 2017·The New England Journal of Medicine·Frédéric B PielDavid C Rees
Aug 13, 2017·Pediatric Blood & Cancer·Laura M Bou-MarounGregory A Yanik
Sep 5, 2017·Pediatric Blood & Cancer·Raffaella ColombattiUNKNOWN Italian Multicenter Study of Hydroxyurea in Sickle Cell Anemia Investigators

❮ Previous
Next ❯

Citations

Nov 7, 2019·Journal of Pediatric Hematology/oncology·Rebekah ShawRobert S Nickel
May 23, 2020·JMIR Research Protocols·Jane S HankinsUNKNOWN Sickle Cell Disease Implementation Consortium
Oct 30, 2020·Journal of Managed Care & Specialty Pharmacy·Hyeun Ah Kang, Jamie C Barner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Clinical Journal of the American Society of Nephrology : CJASN
Tamar SpringelSusan Furth
Journal of Burn Care & Research : Official Publication of the American Burn Association
Krista K WheelerRajan K Thakkar
© 2022 Meta ULC. All rights reserved